于本交易完成后，华西康圣达将成为公司间接全资附属公司。经董事会审慎评估，董事会认为本交易符 合公司及股东整体利益，具体而言：(一)华西康圣达作为集团"全国特检网络+区域中心实验室"战略在 西南地区的核心平台，已发展成为覆盖四川、重庆、云南及贵州的区域性高端特检服务提供商，在肿瘤 早筛、分子诊断等领域具备规模化检测能力与成熟经验。本次实现全资控股将有助于集团加强对华西康 圣达业务运营及战略方向的统筹管理，确保集团整体战略在西南地区高效、一致地执行；(二)作为具备 领先优势的第三方医学检验(ICL)平台，华西康圣达将有力支撑集团"ICL+IVD"双轨发展战略，切实推 动"以ICL驱动IVD产品开发，以IVD反哺ICL服务升级"的协同效应；(三)公司将全面主导华西康圣达的 管理层任命、绩效考核及资源配置，进一步提升跨区域项目(如区域检验中心共建、基层医疗机构合作 等)的执行效率。公司亦将进一步延续和深化与四川大学华西医院的临床与科研合作，并在此基础上更 好地整合西南地区的渠道、技术与医疗资源，强化区域一体化运营能力。 格隆汇11月25日丨康圣环球(09960.HK)公告，武汉康圣达(一家中国综合实体)透过北交所公开 ...

11月14日，《自然》杂志官网公布"2024自然指数-科研城市"排名，广州首次跃居全球第六 20日，广东省科学技术奖公布，广州再创佳绩，占全省获奖总数的65.6% 21日，2025年中国科学院、中国工程院院士增选结果正式揭晓，曾木圣、陈新、杨中民、徐瑞华、黄险波5位广州科学家入选，占全省5/9 近日，广州科创佳报频传。 亮眼成绩背后，是广州多年来以人才为科技创新发展核心，在创新链上勇于投入、默默耕耘的"开花结果"。有人于实验室坚 守，点亮"从0到1"的原创星火；有人进行概念验证，让"从1到10"的雏形淬火成器；有人奔赴产线，促成产业"从10到100"的百花齐放。人才之潮，百川赴 海；金融之风，鼓帆助航；创新之轮，飞旋疾驰。如今，广州结下累累科创硕果，正似木棉欲燃，照彻南天。 企业造"士" 创新主体地位不断凸显 当前， 广州的科技企业数量已达1.35万家，比2015年翻了7倍。 企业是科技创新的主体，科技企业已成为我国引领科技创新和产业创新的主导力量，同时 也成为培养科技人才的主战场。 新晋5位两院院士中， 黄险波院士的身份十分显眼，他担任金发科技股份有限公司首席技术官、高分子材料资源高质化利用国家重点实验室主 ...

2025.11. 14 兰卫医学今年前三季度计提各项资产减值准备共计1673.86万元，其中计提的应收款项计提坏账准备的金额也达到1350.18万元。整体资产减值计提，共 减少了公司合并报表净利润1570.47万元。 据第一财经记者不完全统计，今年前三季度，A股中至少有7家医学检验企业归属于上市公司股东的净利润处于亏损中。这7家企业中，有6家企业2024年 归属于上市公司股东的净利润已经出现亏损。 具 体 看 ， 谱 尼 测 试 （ 300887.SZ ） 、 润 达 医 疗 （ 603108.SH ） 、 达 安 基 因 （ 002030.SZ ） 、 凯 普 生 物 、 金 域 医 学 （ 603882.SH ） 、 华 大 基 因 （300676.SZ）、兰卫医学（301060.SZ）今年前三季度归属于上市公司股东的净利润分别亏损1.99亿元、1.63亿元、1.41亿元、1.28亿元、7960.95 万元、2138.7万元、66.77万元。 虽然迪安诊断（300244.SZ）今年前三季度归属于上市公司股东的净利润5670.48万元，但同比下降56.67%。 检验领域集采降价、检验收费价格下降，导致医学检 ...

Core Insights - The medical testing industry is facing significant challenges due to increased accounts receivable and declining profits, particularly following the COVID-19 pandemic [1][4][5] Group 1: Accounts Receivable and Financial Performance - Four companies have accounts receivable exceeding 2 billion yuan, with Capbio (凯普生物) involved in lawsuits to recover 357 million yuan in overdue payments [1] - In the first three quarters of this year, at least seven medical testing companies reported net losses attributable to shareholders, with six of them expected to continue this trend into 2024 [1] - Specific losses reported include: Puni Testing (谱尼测试) at 199 million yuan, RunDa Medical (润达医疗) at 163 million yuan, and Capbio at 128 million yuan [1] Group 2: Impact of Price Reductions and Impairment Provisions - Price reductions in the testing sector have led to widespread profit shrinkage among medical testing companies, with some firms making impairment provisions for accounts receivable [4] - Companies like KingMed Diagnostics (金域医学) have made significant impairment provisions, totaling 345 million yuan, primarily for accounts receivable, which reduced their consolidated profit by the same amount [4] - Lanwei Medical (兰卫医学) reported a total impairment provision of 16.73 million yuan, with 13.50 million yuan specifically for accounts receivable [5] Group 3: Recovery Trends and Future Outlook - The Ministry of Finance has indicated a commitment to debt reduction policies, which may accelerate the collection of accounts receivable from public hospitals [5] - Companies are implementing strategies to manage accounts receivable more effectively, with Puni Testing focusing on tailored collection strategies for major clients [6] - DiAn Diagnostics (迪安诊断) anticipates improved collection trends in the second half of the year, with expectations that all COVID-related accounts receivable will be fully provisioned by year-end [5][6]

Core Viewpoint - Eddiecon Holdings (09860) announced the acquisition of 100% of the issued shares of Crown Bioscience International for a total purchase price of $204 million, which aligns with the company's strategy to expand its product portfolio and is expected to bring long-term strategic benefits [1][2]. Group 1: Acquisition Details - The buyer, Miramar Lifesciences Limited, a wholly-owned subsidiary of Eddiecon, entered into a share purchase agreement with the seller, JSR Life Sciences, LLC, regarding the acquisition of the target company [1]. - Upon completion of the transaction, Crown Bioscience International will become a wholly-owned subsidiary of Miramar Lifesciences Limited [1]. - The target company is a global Contract Research Organization (CRO) focused on advancing precision medicine in oncology, immuno-oncology, and other therapeutic areas [1]. Group 2: Company Operations - Eddiecon primarily provides Integrated Clinical Laboratory (ICL) services, along with medical testing, clinical trials, research services, health management, and pathology consultation services [1]. - The company focuses on research and development in core disease areas such as infectious diseases, women's health, solid tumors, perinatal and pediatric care, and hematology, covering multiple disciplines including internal medicine, pediatrics, obstetrics and gynecology, oncology, and neurology [1].

Core Viewpoint - The acquisition of Crown Bioscience International by Miramar Lifesciences Limited for a total purchase price of $204 million is expected to enhance the product portfolio of the company and provide long-term strategic benefits [1][2]. Company Overview - The target company, Crown Bioscience International, is a global Contract Research Organization (CRO) focused on advancing precision medicine in oncology, immuno-oncology, and other therapeutic areas [1]. - The company collaborates with biotechnology and pharmaceutical firms to accelerate drug development through integrated preclinical, translational, and clinical biomarker services [1]. Strategic Rationale - The board believes that the acquisition aligns with the group's development strategy to expand its product offerings [2]. - The acquisition is anticipated to bring long-term and strategic benefits to the company [2].

Core Viewpoint - Awei Technology Co., Ltd. has announced that its wholly-owned subsidiary, Hunan Awei Medical Testing Co., Ltd., has obtained a medical institution practice license, allowing it to provide third-party medical testing services, which is expected to create a new growth point for the company [1][2]. Group 1: License Acquisition - Hunan Awei Medical Testing Co., Ltd. received the medical institution practice license from the Health and Health Bureau of Hunan Xiangjiang New District [1]. - The license is valid from November 4, 2025, to November 3, 2030, and covers various diagnostic specialties including clinical microbiology and clinical chemistry [1]. Group 2: Impact on Business - The acquisition of the license enables the company to integrate its existing testing instruments and reagents with testing services, promoting a "device + service" business model [2]. - The impact on the company's performance post-launch of the testing laboratory remains uncertain due to factors such as industry supply and demand, market competition, and brand promotion [2]. Group 3: Investor Communication - The company will hold a third-quarter performance briefing on November 24, 2025, to discuss its operational results and financial status, allowing investors to engage in Q&A [6][7]. - Investors can submit questions from November 17 to November 21, 2025, through the Shanghai Stock Exchange Roadshow Center [8].

Core Viewpoint - Aiwei Technology (688067.SH) has received a medical institution practice license for its wholly-owned subsidiary, Hunan Aiwei Medical Laboratory Co., Ltd, enabling it to provide third-party medical testing services, which will create new business growth opportunities and integrate existing testing instruments and reagents with testing services into a "device + service" business model [1] Group 1 - The company has obtained a medical institution practice license from the Hunan Xiangjiang New Area Health Bureau [1] - Hunan Aiwei Medical Laboratory Co., Ltd will officially offer third-party medical testing services [1] - This development is expected to open new business growth points for the company [1] Group 2 - The integration of existing testing instruments and reagents with testing services will enhance the company's offerings [1] - The company aims to create a comprehensive "device + service" business model [1]

Core Viewpoint - Aiwei Technology (688067.SH) has received a medical institution practice license for its wholly-owned subsidiary, Hunan Aiwei Medical Laboratory Co., Ltd, enabling it to officially provide third-party medical testing services [1] Group 1: Business Expansion - The acquisition of the medical institution practice license opens a new growth avenue for the company [1] - This development allows for the integration of existing testing instruments and reagent consumables with testing services, creating a "device + service" integrated business model [1]

Core Viewpoint - The company has received a medical institution practice license for its subsidiary, which will enable it to provide third-party medical testing services, thus creating new business growth opportunities and promoting an integrated "equipment + service" business model [1] Group 1 - The subsidiary, Hunan Aiwei Medical Testing Co., Ltd., has obtained a medical institution practice license from the Hunan Xiangjiang New Area Health and Health Bureau [1] - The license is valid from November 4, 2025, to November 3, 2030, for the facility named Changsha Aiwei Medical Testing Laboratory [1] - The acquisition of this license will allow the company to officially offer third-party medical testing services [1]